Niagen Bioscience Files $125M Universal Shelf, Launches $50M ATM Program Amidst 52-Week Lows
NAGE is trading near its 52-week low of $3.29 (2.1% above the low) on elevated volume (2.8× avg).
Summary
Niagen Bioscience filed a universal shelf registration for $125 million and launched a new $50 million At-The-Market (ATM) common stock offering, signaling significant potential dilution for shareholders as the stock trades near its 52-week low.
Key Events · Financing and Capital Events · NAGE
-
New Universal Shelf Registration
The company filed an S-3 universal shelf registration statement, authorizing the sale of up to $125 million in common stock, debt securities, warrants, and units from time to time.
-
Launches $50 Million At-The-Market (ATM) Offering
A prospectus supplement within the S-3 details a new At-The-Market (ATM) offering program to sell up to $50 million of common stock through Canaccord Genuity LLC and Roth Capital Partners, LLC.
-
Significant Potential Dilution
The company anticipates an immediate dilution in net tangible book value of $2.12 per share for new investors, assuming the full $50 million is sold at an offering price of $3.45 per share. If all authorized shares were issued, dilution would be 88.38%.
-
Capital Raise Near 52-Week Lows
The offering is being conducted while the company's stock is trading near its 52-week low of $3.29, exacerbating the dilutive impact on existing shareholders.
Analysis · NAGE · Life Sciences
Niagen Bioscience has filed a universal shelf registration statement for up to $125 million in various securities, including common stock, debt, and warrants. Critically, this filing also launches a new At-The-Market (ATM) offering program to sell up to $50 million of common stock. This capital raise is substantial relative to the company's market capitalization and comes as the stock trades near its 52-week low. The company explicitly states that new investors will experience an immediate and substantial dilution of $2.12 per share if the $50 million is sold at the assumed price of $3.45 per share. This follows a recent 10-Q filing that reported a 67% drop in Q1 operating income and negative operating cash flow, indicating a pressing need for capital to extend its financial runway.
At the time of this filing, NAGE was trading at $3.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $272.4M. The 52-week trading range was $3.29 to $14.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.